Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Thursday that the US Food and Drug Administration (FDA) has granted Priority Review to the nipocalimab Biologics License Application (BLA) for the treatment of antibody-positive generalised myasthenia gravis (gMG).
This decision is supported by positive results from the Phase 3 Vivacity-MG3 study, which demonstrated significant improvement in disease control with nipocalimab plus standard of care compared with placebo plus standard of care.
gMG is a rare autoimmune disease affecting approximately 700,000 people globally. Priority Review typically results in a shorter FDA review period, aiming to expedite the availability of potentially life-changing therapies.
J&J has also submitted a Marketing Authorisation Application for nipocalimab in gMG to the European Medicines Agency and received Breakthrough Therapy Designation from the FDA for the treatment of Sjögren's disease.
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
Syndax Pharmaceuticals grants share purchase inducement awards to six new employees
Hippo Pharmacy launches fast, free delivery on orders over USD150
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review